sampl
collect
phase
random
studi
registr
sixti
adult
enrol
three
group
sixteen
subject
per
group
receiv
hcv
adjuv
administ
intramuscularli
week
subject
per
group
receiv
salin
placebo
assay
perform
use
biotinyl
peptid
repres
known
linear
epitop
previous
sera
test
dilut
cutoff
set
optic
densiti
od
neg
control
normal
human
serum
valu
express
positiveneg
ratio
pn
ratio
antibodi
deplet
sera
previous
total
ng
biotinyl
peptid
unrel
peptid
control
peptid
repres
protein
influenza
viru
mix
magnet
dynabead
invitrogen
carlsbad
ca
block
nonspecif
bind
site
salin
pb
bead
incub
human
serum
minut
room
temperatur
remov
antibodi
bead
captur
magnet
supernat
collect
analysi
hcvcc
chimer
viru
gener
previous
region
base
consensu
sequenc
access
region
aa
hcv
polyprotein
share
homolog
genotyp
sequenc
use
phase
vaccin
studi
access
http
neutral
antibodi
titer
determin
use
cell
perform
dilut
sera
mix
hcvcc
focu
form
unit
ffu
previous
give
start
dilut
hour
cell
fix
formaldehyd
stain
core
mous
mab
dilut
develop
abc
kit
vector
laboratori
burlingam
ca
previous
foci
count
use
autom
count
system
cellular
technolog
limit
cleveland
oh
use
biospot
softwar
two
type
hcv
pseudotyp
particl
hcvpp
carri
envelop
protein
hcv
genotyp
access
access
gener
plasmid
obtain
nation
institut
health
aid
reagent
program
encod
firefli
luciferas
report
gene
encod
either
cotransfect
cell
hour
supernat
cell
harvest
clarifi
centrifug
minut
neg
control
pseudoparticl
without
envelop
protein
gener
neutral
antibodi
titer
determin
use
cell
describ
mix
sera
dilut
set
amount
hcvpp
rel
luciferas
unit
rlu
per
reaction
hcvpp
infect
perform
previous
use
sampl
triplic
hour
media
remov
cell
lyse
freez
thaw
report
lysi
buffer
promega
madison
wi
twenti
microlit
use
determin
luciferas
activ
use
luciferas
assay
system
promega
read
use
luminomet
berthold
technolog
oak
ridg
tn
result
well
obtain
rlu
inhibitori
dose
neutral
titer
calcul
describ
titer
assign
sampl
inhibit
obtain
dilut
sampl
compar
use
wilcoxon
test
pair
data
correl
analysi
perform
use
graphpad
softwar
version
graphpad
softwar
inc
san
diego
ca
p
valu
consid
signific
total
blind
sampl
test
immunosorb
assay
elisa
reactiv
peptid
repres
aa
aa
blind
sampl
also
treat
deplet
antibodi
mock
treat
peptid
test
elisa
neutral
assay
complet
studi
sampl
unblind
statist
analyz
base
upon
treatment
group
reactiv
peptid
blind
panel
consist
sampl
vaccin
subject
placebo
subject
subject
repres
two
sampl
one
prevaccin
one
postvaccin
distribut
sampl
group
postplacebo
vaccin
shown
fig
within
placebo
group
preplacebo
sampl
test
neg
epitop
fig
wherea
two
postplacebo
sampl
demonstr
low
reactiv
fig
among
prevaccin
sampl
six
test
posit
pn
four
sampl
test
posit
epitop
fig
vaccin
reactiv
either
epitop
increas
significantli
p
fig
sampl
test
posit
least
one
epitop
fig
signal
chang
subject
show
prevaccin
reactiv
suggest
presenc
antibodi
sampl
use
postplacebo
prevaccin
sampl
n
calcul
elisa
specif
respect
frequenc
sampl
test
posit
postvaccin
correl
dose
vaccin
given
studi
fig
percentag
seroposit
sampl
base
upon
elisa
data
found
subject
immun
hcv
subject
immun
subject
immun
elisa
test
blind
sampl
classifi
posit
doubl
posit
six
posit
posit
neg
epitop
doubl
neg
address
whether
level
antibodi
influenc
neutral
activ
sera
treat
sampl
regardless
initi
elisa
result
peptid
deplet
specif
antibodi
control
treat
sampl
parallel
peptid
sampl
test
mock
treat
treat
elisa
figur
show
elisa
signal
sampl
base
upon
whether
sampl
test
doubl
posit
n
posit
n
posit
n
doubl
neg
n
initi
elisa
independ
treatment
group
sampl
treat
observ
signific
decreas
p
signal
compar
sampl
fig
also
observ
signific
decreas
elisa
signal
p
six
sampl
test
posit
fig
major
sampl
neg
antibodi
elisa
posit
doubl
neg
also
show
decreas
signal
fig
found
signific
p
group
could
owe
presenc
sampl
low
level
antibodi
class
posit
origin
elisa
analysi
owe
remov
sampl
background
antibodi
bound
low
specif
deplet
treatment
sampl
test
neutral
assay
use
hcvcc
chimera
deplet
antibodi
serum
sampl
increas
titer
sampl
p
fig
sampl
test
neutral
mock
treatment
observ
slight
increas
titer
three
six
sampl
although
increas
found
nonsignific
p
fig
sampl
also
observ
increas
titer
sampl
p
fig
although
p
valu
signific
analysi
suggest
trend
sampl
display
increas
neutral
activ
could
indic
presenc
low
level
antibodi
sampl
cutoff
initi
assay
sampl
fig
score
titer
treatment
deplet
observ
increas
titer
two
sampl
overal
chang
titer
group
signific
p
hypervari
region
region
lie
directli
upstream
epitop
exclud
role
antibodi
interact
antibodi
perform
neutral
assay
use
hcvpp
carri
protein
access
hcvpp
carri
protein
access
sampl
test
antibodi
elisa
use
peptid
specif
sequenc
group
demonstr
highest
reactiv
peptid
http
gener
observ
higher
titer
use
hcvpp
system
hcvcc
system
hcvpp
fig
howev
use
hcvpp
system
observ
similar
impact
titer
antibodi
deplet
sera
regardless
whether
hcvpp
use
deplet
antibodi
serum
sampl
increas
titer
sampl
p
hcvpp
fig
sampl
p
hcvpp
fig
similar
observ
hcvcc
titer
increas
observ
littl
chang
titer
sampl
hcvpp
p
respect
fig
sampl
observ
slight
increas
titer
treat
sampl
fig
f
chang
found
signific
use
hcvpp
p
signific
use
hcvpp
p
consist
hcvcc
data
observ
signific
chang
titer
sera
treatment
test
either
hcvpp
variant
data
shown
mab
region
previous
shown
sampl
chronic
infect
patient
also
shown
contain
neutral
antibodi
target
observ
decreas
titer
sampl
test
deplet
peptid
suggest
antibodi
recogn
epitop
contribut
greatli
overal
neutral
activ
sampl
assess
whether
level
antibodi
associ
neutral
analyz
correl
titer
antibodi
level
peptid
mock
treatment
sampl
classifi
antibodi
posit
either
epitop
first
perform
analysi
particl
hcvcc
hcvpp
clariti
data
shown
hcvcc
analysi
analys
perform
hcvpp
studi
return
similar
result
sampl
level
show
signific
correl
titer
fig
b
valu
analys
less
howev
treatment
peptid
level
antibodi
correl
significantli
titer
fig
p
spearman
correl
coeffici
r
wherea
reduc
level
treat
sampl
correl
higher
lower
titer
despit
increas
titer
mani
sampl
fig
perform
analysi
hcvpp
found
signific
correl
p
p
antibodi
level
neutral
titer
sampl
fig
b
antibodi
remov
observ
similar
increas
titer
correl
antibodi
note
particl
fig
p
spearman
correl
coeffici
r
also
similar
observ
particl
reduc
antibodi
level
treat
sampl
correl
significantli
higher
lower
titer
p
fig
data
suggest
level
antibodi
strong
indic
neutral
capac
sampl
presenc
low
amount
antibodi
subsequ
find
ask
whether
ratio
level
could
use
indic
neutral
abil
sampl
ratio
plot
titer
found
hcvcc
hcvpp
major
sampl
posit
neutral
activ
low
ratio
fig
howev
larg
number
sampl
low
ratio
display
detect
neutral
activ
result
reflect
complex
interact
antibodi
level
direct
comparison
titer
simpli
use
predict
neutral
capac
sampl
minimum
antibodi
threshold
must
met
achiev
detect
neutral
develop
prophylact
vaccin
hcv
remain
challeng
current
data
suggest
would
advantag
includ
hcv
structur
protein
circul
viru
infect
individu
exist
popul
variabl
throughout
genom
glycoprotein
exhibit
higher
level
variabl
among
genotyp
thu
gener
antibodi
conserv
epitop
envelop
protein
would
benefici
develop
effect
vaccin
design
induc
neutral
antibodi
mab
recogn
conserv
epitop
locat
aa
within
shown
inhibit
bind
antibodi
region
shown
induc
vaccin
natur
time
antibodi
downstream
region
aa
also
induc
interfer
neutral
studi
blind
serum
sampl
deriv
phase
clinic
trial
healthi
volunt
support
hypothesi
antibodi
could
interfer
neutral
activ
sera
also
contain
antibodi
demonstr
use
viru
pseudotyp
virus
carri
hcv
envelop
genotyp
remov
antibodi
sera
result
increas
neutral
activ
sampl
p
fig
signific
chang
neutral
observ
sampl
posit
sampl
neg
epitop
observ
increas
neutral
activ
sampl
becam
signific
p
use
hcvpp
fig
could
owe
low
amount
antibodi
present
sampl
juxtaposit
region
could
potenti
impact
interf
effect
antibodi
present
studi
use
hcvpp
indic
case
observ
similar
effect
treatment
titer
use
hcvpp
use
hcvcc
hcvpp
sampl
treat
studi
eight
display
increas
neutral
activ
treatment
remain
neg
neutral
antibodi
howev
sampl
contain
highest
ratio
antibodi
could
indic
threshold
antibodi
ratio
need
achiev
neutral
andor
antibodi
sampl
investig
concept
antibodi
ratio
although
neutral
activ
serum
sampl
associ
low
ratio
absolut
correl
fig
suggest
interact
exist
pair
may
determin
neutral
serum
sampl
interfer
antibodi
support
signific
correl
antibodi
titer
neutral
titer
antibodi
remov
sampl
fig
use
hcvcc
hcvpp
system
found
lack
correl
level
neutral
fig
suggest
antibodi
induc
vaccin
contribut
greatli
overal
neutral
activ
sampl
find
signific
correl
antibodi
level
neutral
use
hcvpp
system
fig
could
owe
higher
level
antibodi
antibodi
present
sampl
signal
act
indic
better
immun
respons
vaccin
correl
longer
observ
treatment
fig
treatment
result
greater
number
sampl
increas
titer
low
signal
oppos
sampl
low
signal
lose
neutral
abil
overal
find
direct
correl
antibodi
level
neutral
system
use
therefor
conclud
antibodi
induc
vaccin
recombin
protein
bind
distinct
residu
region
could
result
interf
phenotyp
instead
neutral
phenotyp
contrast
number
public
show
antibodi
direct
region
inhibit
viral
infect
residu
within
region
involv
howev
previou
studi
also
shown
function
qualiti
antibodi
differ
depend
upon
specif
epitop
recogn
critic
bind
major
neutral
activ
detect
assay
appear
associ
antibodi
consist
previou
report
sampl
phase
clinic
given
region
highli
conserv
recent
subset
sampl
cohort
shown
bind
competit
mab
recogn
residu
within
well
residu
locat
elsewher
support
potenti
vaccin
sampl
test
activ
genotyp
possibl
studi
use
treat
sera
owe
limit
amount
serum
sampl
sequenc
region
use
chimer
viru
differ
slightli
use
recombin
vaccin
http
greatest
variat
locat
least
part
neutral
activ
serum
sampl
previous
shown
direct
observ
significantli
higher
titer
use
hcvpp
compar
hcvpp
exclud
interact
antibodi
antibodi
neutral
possibl
antibodi
recogn
region
act
synergist
addit
could
compet
bind
neutral
given
posit
epitop
analys
complex
although
import
understand
mechan
hcv
neutral
polyclon
sera
beyond
scope
studi
mechan
antibodi
interfer
still
elucid
given
adjac
hcv
protein
interfer
could
therefor
occur
steric
hindranc
prevent
bind
antibodi
conform
chang
induc
bind
interestingli
structur
studi
shown
could
adopt
differ
conform
indic
structur
flexibl
site
flexibl
confirm
crystal
structur
hcv
complex
structur
interact
occur
region
downstream
encompass
region
part
region
shown
form
part
conform
epitop
recogn
broadli
neutral
structur
studi
confirm
epitop
includ
portion
could
account
antibodi
exhibit
neutral
activ
presenc
altern
conform
virion
could
chang
specif
andor
affin
antibodi
recognit
two
epitop
thu
constitut
strategi
hcv
evad
humor
immun
respons
altern
antibodi
could
enhanc
infect
could
compet
neutral
effect
antibodi
includ
data
seem
support
mechan
given
invers
correl
level
antibodi
neutral
fig
remov
antibodi
group
sampl
result
signific
increas
neutral
activ
p
fig
howev
sampl
size
small
n
provid
suffici
statist
power
remov
antibodi
result
increas
titer
subset
sampl
foci
number
rlu
signal
analyz
respect
level
observ
increas
foci
rlu
associ
increas
amount
data
shown
indic
antibodi
induc
vaccin
enhanc
viral
infect
overal
studi
shown
antibodi
epitop
induc
vaccin
recombin
protein
induct
antibodi
dose
depend
group
patient
receiv
highest
dose
vaccin
contain
highest
number
sampl
compar
group
receiv
doubl
posit
number
analys
use
sampl
deplet
antibodi
show
signific
effect
antibodi
neutral
activ
antibodi
hcvcc
hcvpp
system
support
previou
hypothesi
antibodi
interfer
function
antibodi
given
potenti
antibodi
prevent
induct
antibodi
interfer
activ
may
lead
improv
qualiti
efficaci
futur
hcv
vaccin
author
name
bold
design
share
authorship
